Sionna Therapeutics (NASDAQ:SION) Downgraded by Lifesci Capital to “Hold”

Lifesci Capital downgraded shares of Sionna Therapeutics (NASDAQ:SION) from a strong-buy rating to a hold rating in a research note published on Monday,Zacks.com reports.

Several other brokerages have also commented on SION. Raymond James Financial lowered Sionna Therapeutics from a “strong-buy” rating to a “market perform” rating in a report on Monday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sionna Therapeutics in a research note on Wednesday, August 5th. Freedom Capital lowered shares of Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, May 20th. JonesTrading cut shares of Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday. Finally, Guggenheim lowered shares of Sionna Therapeutics from a “buy” rating to a “neutral” rating in a report on Monday. One analyst has rated the stock with a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Sionna Therapeutics has a consensus rating of “Hold” and a consensus target price of $42.22.

Sionna Therapeutics Stock Up 13.3%

Sionna Therapeutics stock opened at $5.10 on Monday. Sionna Therapeutics has a 52 week low of $4.01 and a 52 week high of $54.97. The business has a 50-day simple moving average of $40.99 and a 200 day simple moving average of $39.92. The stock has a market cap of $230.58 million, a price-to-earnings ratio of -2.34 and a beta of 1.32.

Sionna Therapeutics (NASDAQ:SION) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.02). On average, research analysts anticipate that Sionna Therapeutics will post -2.66 earnings per share for the current year.

Insider Transactions at Sionna Therapeutics

In related news, Director Peter A. Thompson sold 115,844 shares of the firm’s stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $45.50, for a total transaction of $5,270,902.00. Following the transaction, the director directly owned 2,555,877 shares of the company’s stock, valued at approximately $116,292,403.50. This trade represents a 4.34% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 115,844 shares of the business’s stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $45.50, for a total value of $5,270,902.00. Following the completion of the sale, the director owned 2,555,877 shares of the company’s stock, valued at $116,292,403.50. The trade was a 4.34% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 403,726 shares of company stock valued at $18,259,354 over the last quarter. Company insiders own 5.10% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Russell Investments Group Ltd. bought a new stake in shares of Sionna Therapeutics in the 3rd quarter worth approximately $30,000. BNP Paribas Financial Markets bought a new position in shares of Sionna Therapeutics during the 2nd quarter valued at $31,000. State of Wyoming bought a new position in shares of Sionna Therapeutics during the 2nd quarter valued at $35,000. GF Fund Management CO. LTD. purchased a new position in Sionna Therapeutics in the 4th quarter worth $36,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in Sionna Therapeutics in the 2nd quarter worth $44,000.

Key Sionna Therapeutics News

Here are the key news stories impacting Sionna Therapeutics this week:

• Negative Sentiment: SION-719 failed its Phase 2 primary endpoint. The experimental cystic-fibrosis treatment did not produce the expected improvement, prompting Sionna to discontinue development of SION-719 as an add-on therapy. The failure eliminates the company’s principal near-term clinical catalyst and raises uncertainty about the value of its broader pipeline. Sionna Therapeutics Halts Lead Cystic Fibrosis Drug After Phase 2 Failure
• Negative Sentiment: The stock dropped roughly 90% to a record low. The magnitude of the decline reflects investors’ reassessment of Sionna’s prospects following the unexpected trial miss and the loss of its lead drug program. Trading volume was also unusually heavy compared with the company’s average. Sionna Therapeutics stock falls 92% after SION-719 trial failure
• Negative Sentiment: Analysts cut their ratings after the clinical setback. BTIG and Guggenheim moved from “buy” to “neutral,” while Raymond James, Citizens JMP and Wedbush also reduced their ratings. Wedbush and RBC set approximately $5 price targets, signaling limited expected upside at current levels. Sionna Discontinues Cystic Fibrosis Drug Following Unfavorable Data
• Neutral Sentiment: Sionna reported mixed results from two cystic-fibrosis programs and plans to refocus its pipeline. However, the company has not yet identified a replacement asset with comparable clinical maturity, leaving its future strategy and financing needs uncertain. Sionna Reports Mixed Trial Results and Refocuses CF Pipeline
• Neutral Sentiment: The failure benefits rival Vertex Pharmaceuticals. Sionna’s unsuccessful trial removes a potential competitor to Vertex’s established cystic-fibrosis franchise, which explains why Vertex shares rose as Sionna’s stock declined. Vertex Shares Rise as Rival Sionna Trial Fails

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.